For adult patients with moderate to severe chronic plaque psoriasis (Ps)

Dramatic skin clearance at 16 weeks

In 2 pivotal trials, HUMIRA-treated patients saw dramatic skin clearance at 16 weeks vs placebo1-3


STUDY DESIGN INTRODUCTIONS

REVEAL was a 52-week randomized, double-blind, placebo-controlled trial in adult patients with moderate to severe chronic plaque psoriasis.1,2 CHAMPION was a 16-week randomized, double-blind, placebo-controlled study of adult patients with moderate to severe plaque psoriasis.1,3

View full study design

PGA

PGA: CLEAR OR MINIMAL5*

(Co-primary Endpoint)

BASELINE PGA: SEVERE

WEEK 16 PGA: MINIMAL

DRAG TO VIEW

Photos are of actual clinical trial patients.5-7 Individual results may vary. The analysis was based on the intention-to-treat population, with missing values imputed as nonresponders.2,3

REVEAL1,2   P<0.001

62%

vs

04%

ACHIEVED A PGA OF CLEAR OR MINIMAL

CHAMPION1,3   P<0.001

73%

vs

11%

ACHIEVED A PGA OF CLEAR OR MINIMAL

HUMIRA 80 mg at week 0, 40 mg EOW starting at week 1 (REVEAL n=814; CHAMPION n=108)

Placebo (REVEAL n=398; CHAMPION n=53)


From the full Prescribing Information for HUMIRA1

The data assessed in the HUMIRA full Prescribing Information included only patients in CHAMPION with a baseline PASI ≥12 and therefore differ from the data shown here.

  • 78% of HUMIRA-treated patients (n=99) achieved PASI 75 improvement at week 16 vs 19% of placebo-treated patients (n=48)1
  • 71% of HUMIRA-treated patients (n=99) achieved a PGA score of clear or minimal at week 16 vs 10% of placebo-treated patients (n=48)1

*PGA of Clear defined as no plaque elevation, no scale, plus or minus hyperpigmentation or diffuse pink or red coloration. Minimal defined as possible, but difficult to ascertain whether there is slight elevation of plaque above normal skin, plus or minus surface dryness with some white coloration, plus or minus up to red coloration.1 PGA of Severe defined as marked plaque elevation typically with hard or sharp edges; coarse, nontenacious scale predominates covering most or all of the lesions; very bright red coloration.

BSA=body surface area; EOW=every other week; OLE=open-label extension; PGA=physician’s global assessment

PASI 75

PASI 755†

(Co-primary Endpoint)

BASELINE PASI: 20.3

WEEK 16 PASI: 4.2

DRAG TO VIEW

Photos are of actual clinical trial patients.5-7 Individual results may vary. The analysis was based on the intention-to-treat population, with missing values imputed as nonresponders.2,3

REVEAL1,2   P<0.001

71%

vs

07%

ACHIEVED PASI 75 IMPROVEMENT

CHAMPION1,3   P<0.001

80%

vs

19%

ACHIEVED PASI 75 IMPROVEMENT

HUMIRA 80 mg at week 0, 40 mg EOW starting at week 1 (REVEAL n=814; CHAMPION n=108)

Placebo (REVEAL n=398; CHAMPION n=53)


From the full Prescribing Information for HUMIRA1

The data assessed in the HUMIRA full Prescribing Information included only patients in CHAMPION with a baseline PASI ≥12 and therefore differ from the data shown here.

  • 78% of HUMIRA-treated patients (n=99) achieved PASI 75 improvement at week 16 vs 19% of placebo-treated patients (n=48)1
  • 71% of HUMIRA-treated patients (n=99) achieved a PGA score of clear or minimal at week 16 vs 10% of placebo-treated patients (n=48)1

PASI 75 represents ≥75% improvement in skin clearance from baseline.

BSA=body surface area; EOW=every other week; OLE=open-label extension; PASI=Psoriasis Area and Severity Index

PASI 90

PASI 902,3,5,6‡

(Secondary Endpoint)

BASELINE PASI: 25.2

WEEK 16 PASI: 1.2

DRAG TO VIEW

REVEAL2   P<0.001

45%

vs

02%

ACHIEVED PASI 90 IMPROVEMENT

CHAMPION3   P<0.001

52%

vs

11%

ACHIEVED PASI 90 IMPROVEMENT

HUMIRA 80 mg at week 0, 40 mg EOW starting at week 1 (REVEAL n=814; CHAMPION n=108)

Placebo (REVEAL n=398; CHAMPION n=53)

Photos are of actual clinical trial patients.5-7 Individual results may vary. The analysis was based on the intention-to-treat population, with missing values imputed as nonresponders.2,3


PASI 90 represents ≥90% improvement in skin clearance from baseline.

BSA=body surface area; EOW=every other week; OLE=open-label extension; PASI=Psoriasis Area and Severity Index

PASI 100

PASI 1002,3,7§

(Secondary Endpoint)

BASELINE PASI: 28.2

WEEK 16 PASI: 0.0

DRAG TO VIEW

REVEAL2   P<0.001

20%

vs

01%

ACHIEVED PASI 100 IMPROVEMENT

CHAMPION3 P<0.004

17%

vs

02%

ACHIEVED PASI 100 IMPROVEMENT

HUMIRA 80 mg at week 0, 40 mg EOW starting at week 1 (REVEAL n=814; CHAMPION n=108)

Placebo (REVEAL n=398; CHAMPION n=53)

Photos are of actual clinical trial patients.5-7 Individual results may vary. The analysis was based on the intention-to-treat population, with missing values imputed as nonresponders.2,3


§PASI 100 represents a 100% improvement in skin clearance from baseline.

BSA=body surface area; EOW=every other week; OLE=open-label extension; PASI=Psoriasis Area and Severity Index